Haematolymphoid screening in flow cytometry

The ClearLLab LS Lymphoid Screen eliminates 14 manual workflow steps, while streamlining five others; and is available through a dry unitised, ready-to-use formulation. ClearLLab has been designed specifically for the fast and accurate identification of haematolymphoid cell populations on the company’s Navios flow cytometer.

            Mario Koksch (Beckman Coulter’s Cytometry Business Unit) said: “Beckman Coulter provides laboratory scientists with the tools they need to standardise and streamline workflow when using high-content flow cytometry in clinical decision-making. By eliminating 14 workflow steps, we empower them to achieve much faster and more consistent turnaround times.”

            Flow cytometry offers significant advantages over other cell-based techniques, such as precision, speed, the preservation of cell viability and cellular functions, and simultaneous measurements of multiple cellular parameters. As Dr Kosch explained: “If survival rates are to be improved, we need to be able to diagnose life-threatening haematolymphoid diseases as quickly as possible. With ClearLLab LS Lymphoid Screen, the laboratory now has the means to speed up the delivery of patient results to clinicians, while having added confidence in their accuracy.”

            The ClearLLab LS Lymphoid Screen is the first of an advanced range of Beckman Coulter clinical flow cytometry products that cater to different global workflow requirements over the next five years. It is compatible with the World Health Organization (WHO) 2008 revised classification of myeloid neoplasms and acute leukaemia. In collaboration with the European Association for Haematopathology and the Society for Haematopathology, WHO made important changes to the classification of these diseases, including new criteria for the recognition of some previously described neoplasms as well as clarification and refinement of the defining criteria for others.